查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464789

皮膚科治療市場：按治療層級、給藥途徑、適應症、最終用戶、分銷管道 - 全球預測 2024-2030

Dermatology Drugs Market by Therapeutic Class (Antifungals, Corticosteroids, Immunosuppressants), Route of Administration (Oral, Parenteral Injection, Topical), Indication Type, End-User, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年皮膚科治療市場規模為314億美元，預計2024年將達342.3億美元，2030年將達到605.6億美元，複合年成長率為9.83%。

皮膚病治療劑包括專門開發和用於治療和管理皮膚病的多種藥物化合物。此類別包括用於治療多種皮膚病的藥物，包括痤瘡、皮膚炎、乾癬、皮膚感染疾病和皮膚癌。皮膚科藥物型態多種形式，包括外用藥物、內服藥物、注射劑和靜脈注射藥物，並且是專門針對有效解決特定症狀而設計的。皮膚科藥物的選擇要考慮病情的嚴重程度、病人的病歷和藥物的作用機轉。全球患有皮膚病的人數不斷增加，推動了對皮膚科治療的需求，因為人口老化使他們更容易患皮膚病。此外，藥物傳遞系統和配方技術的創新正在提高皮膚病治療的有效性和便利性。接受美容治療的文化接受度和經濟能力的提高正在推動對美容皮膚科治療的需求。然而，與新的和創新的皮膚病治療相關的高成本可能會限制市場的成長。與皮膚科藥物相關的安全問題和副作用可能會導致患者依從性和利用率降低。儘管如此，個人化醫療（根據個人遺傳體質提供量身定做的治療）以及微創治療方法的開發等開拓領域具有巨大的業務成長潛力。此外，投資天然和有機皮膚科產品的研究可以幫助滿足消費者對永續、無副作用選擇不斷成長的需求。擴大皮膚科遠距遠端醫療服務還可以改善患者的就診機會和便利性並提高競爭力。

主要市場統計
基準年[2023] 314億美元
預測年份 [2024] 342.3億美元
預測年份 [2030] 605.6億美元
複合年成長率（%） 9.83%

治療層級：免疫抑制劑在皮膚科領域的普及，用於治療嚴重或難治性皮膚病

抗真菌藥物在治療由真菌感染引起的皮膚病中發揮重要作用。這些藥物透過靶向真菌細胞膜並抑制其生長和複製來發揮作用。抗真菌治療包括局部用藥，如乳霜和軟膏，以及全身性用藥，如內服藥物和靜脈注射。皮質類固醇因其強大的發炎和免疫抑製作用而成為治療許多皮膚病的基石。這些藥物可以局部、口服或注射給藥，可有效控制乾癬、濕疹和皮膚炎等疾病的症狀。皮質類固醇的作用是複製腎上腺分泌的激素的作用，減少發炎並抑制免疫系統反應。免疫抑制劑在皮膚科中用於治療對常規治療方法無反應的嚴重或難治性皮膚病。透過抑制免疫系統，這些藥物可以減輕發炎並幫助緩解自體免疫皮膚病的症狀，例如嚴重濕疹、乾癬和大皰性水痘。考慮到感染疾病風險增加以及與免疫系統抑制相關的其他潛在副作用，應謹慎使用Cyclosporine、Azathioprine和Methotrexate等免疫抑制劑。源自維生素 A 的類視色素因其促進細胞更新和減少發炎的能力而廣泛應用於皮膚科。可用於治療痤瘡、乾癬和光老化。類視色素透過與皮膚細胞上的維生素A酸受體相互作用來調節細胞分化、增殖和凋亡。此類藥物包括維A酸、阿達帕林和他扎羅汀等外用藥物，以及治療嚴重痤瘡的異維A酸等內服藥物。

終端使用者：由於注重外表和健康的社會趨勢不斷增強，美容和皮膚科診所的趨勢強勁。

美容診所和皮膚科診所是實施和開立皮膚科治療處方的主要場所。這些專科診所治療各種皮膚問題，從常見的皮膚病到整容手術。隨著社會越來越關注外表和健康，對醫療和美容治療的需求不斷增加。皮膚科診所對於提供專業護理並透過技術創新推動皮膚科治療和手術的進步至關重要。診斷中心和實驗室為皮膚病的準確診斷和監測提供基本服務，在皮膚科生態系統中發揮重要作用。皮膚科治療受診斷結果的影響很大，因此需要準確、全面的檢測能力。這些設施根據診斷報告製定個人化治療計劃，並幫助最佳化患者治療效果。基因檢測和分子診斷等診斷技術的進步使這些中心處於確定個別患者藥物療效和潛在副作用的最前沿。醫院是應用皮膚科治療的重要部門，特別是對於需要多學科治療的重症和急性皮膚病。醫院提供住院和門診服務，設有專門的皮膚科病房和科室來處理複雜的病例。接觸廣泛的醫療保健專業人員可確保提供全面的護理，包括最新的皮膚科藥物。

區域洞察

美國由於其強大的醫療基礎設施、高昂的醫療成本以及大型製藥公司的存在而在皮膚科藥物市場佔據主導地位。這個市場的特點是對治療乾癬和異位性皮膚炎等嚴重皮膚病的生物製藥和新療法有很高的需求。 FDA 對加快核准的監管支持也是一個關鍵促進因素。 EMEA（歐洲、中東和非洲）地區呈現出皮膚病治療的多樣化模式，其中西歐是最發達的市場。該地區的法規結構非常嚴格，由 EMA監督藥品核准。不斷增加的研發投資和優惠的報銷政策正在推動歐洲市場的發展。儘管中東和非洲的市場佔有率很小，但由於醫療保健基礎設施的提高和改善，它們正在成長。在快速都市化、可支配收入增加和龐大患者群的推動下，亞太地區皮膚病治療呈現成長趨勢。中國和印度等國家處於這方面的前沿，政府實施了有利於吸引外國投資進入醫療保健領域的政策。該地區的學名藥普及很高，提供了具有成本效益的治療選擇。

FPNV定位矩陣

FPNV 定位矩陣對於評估皮膚科治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對皮膚病治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.皮膚科治療市場的市場規模與預測是多少？

2.皮膚科藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.皮膚科治療市場的技術趨勢和法規結構是什麼？

4.皮膚科治療市場主要廠商的市場佔有率是多少？

5.進入皮膚科用藥市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 乾癬、濕疹、痤瘡和皮膚癌等皮膚病的增加
      • 藥物開發方面的技術進步和強大的皮膚科治療產品線
      • 擴大採用生物製藥來抗治療性疾病
    • 抑制因素
      • 嚴格而漫長的監管核准流程
    • 機會
      • 對個人化醫療的新投資和遠端醫療應用的增加
      • 皮膚科產品向天然和有機成分的重大轉變
    • 任務
      • 處理成本高、監管政策嚴格
  • 市場區隔分析
    • 治療層級：免疫抑制劑在皮膚科的普及，用於治療嚴重或難治性皮膚病
    • 最終用戶：社會對外表和健康的日益重視導致人們對美容和皮膚科診所的興趣增加。
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章皮膚科治療藥物市場：依治療層級

  • 抗真菌藥物
  • 皮質類固醇
  • 免疫抑制劑
  • 類視色素A

第7章 皮膚科治療藥物市場：依給藥途徑

  • 口服
  • 腸外注射
  • 局部的

第8章皮膚科藥物市場：依適應症分類

  • 粉刺
  • 異位性皮膚炎
  • 乾癬
  • 皮膚癌

第9章皮膚科治療藥物市場：依最終使用者分類

  • 美容/皮膚科診所
  • 診斷中心及實驗室
  • 醫院

第10章皮膚科治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房

第11章北美和南美皮膚科藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區皮膚科治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲皮膚科治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • Almirall 與微軟宣布合作開發皮膚病新治療方法
    • FDA核准Arcutis 的 ZORYVE（羅氟司特）外用泡沫 0.3% 用於治療脂漏性皮膚炎
    • 禮來公司 (Eli Lilly) 推出乾癬治療藥物，進軍皮膚科
  • 戰略分析和建議

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-950610B5BBD5

[185 Pages Report] The Dermatology Drugs Market size was estimated at USD 31.40 billion in 2023 and expected to reach USD 34.23 billion in 2024, at a CAGR 9.83% to reach USD 60.56 billion by 2030.

Dermatology drugs encompass a wide array of pharmaceutical compounds specifically developed and utilized for the treatment and management of skin disorders and diseases. This category includes medications designed to treat a vast range of dermatological conditions such as acne, dermatitis, psoriasis, skin infections, and skin cancers, among others. Dermatology drugs may come in various forms, including topical applications, oral medications, injections, and infusions, tailored to address specific conditions effectively. The selection of a dermatology drug involves considerations of the condition's severity, the patient's medical history, and the drug's mechanism of action. An increasing elderly population is more prone to skin diseases, and The rising number of individuals suffering from skin diseases globally fuels the demand for dermatology drugs. Further, innovations in drug delivery systems and formulation technology enhance the efficacy and convenience of dermatology drugs. Growing cultural acceptance and economic ability to undergo cosmetic treatments have boosted the demand for aesthetic dermatology drugs. However, the high cost associated with new and innovative dermatology drugs can limit the market growth. Safety concerns and side effects associated with dermatology drugs can lead to decreased patient compliance and usage. Nevertheless, exploring areas such as personalized medicine, which tailors treatment to individual genetic makeup, and the development of minimally invasive treatment options holds significant promise for business growth. Furthermore, investing in the research of natural and organic dermatological products can meet the increasing consumer demand for sustainable and side-effect-free options. Expanding telemedicine services for dermatology can also provide a competitive edge by enhancing patient access and convenience.

KEY MARKET STATISTICS
Base Year [2023] USD 31.40 billion
Estimated Year [2024] USD 34.23 billion
Forecast Year [2030] USD 60.56 billion
CAGR (%) 9.83%

Therapeutic Class: Proliferation of immunosuppressants in dermatology for the treatment of severe or refractory skin conditions

Antifungal drugs play a critical role in the management of dermatological conditions caused by fungal infections. These medications work by targeting the cell membrane of fungi, disrupting their growth and replication. The scope of antifungal therapies encompasses topical agents, such as creams and ointments, as well as systemic treatments, including oral and intravenous medications. Corticosteroids are a cornerstone in the treatment of numerous dermatological conditions due to their potent anti-inflammatory and immunosuppressive properties. These drugs can be administered topically, orally, or via injections and are effective in managing symptoms of diseases such as psoriasis, eczema, and dermatitis. Corticosteroids work by replicating the effects of hormones produced by the adrenal glands, reducing inflammation, and suppressing the immune system's response. Immunosuppressants are utilized in dermatology for the treatment of severe or refractory skin conditions that do not respond well to conventional therapies. By suppressing the immune system, these drugs help reduce inflammation and alleviate symptoms of autoimmune skin diseases such as severe eczema, psoriasis, and bullous pemphigoid. Immunosuppressants, including cyclosporine, azathioprine, and methotrexate, must be prescribed with caution, considering the increased risk of infections and other potential adverse effects associated with immune system suppression. Retinoids, derived from Vitamin A, are extensively used in dermatology for their ability to promote cell turnover and reduce inflammation. They are valuable in treating acne, psoriasis, and photoaging. Retinoids work by interacting with retinoic acid receptors on skin cells, leading to the modulation of cell differentiation, proliferation, and apoptosis. This class includes topical formulations, such as tretinoin, adapalene, and tazarotene, as well as oral medications, including isotretinoin for severe acne.

End-User: High inclination towards aesthetic and dermatology clinics owing to increasing societal emphasis on appearance and wellness

Aesthetic and dermatology Clinics are primary venues for administering and prescribing dermatology drugs. These specialized clinics cater to a wide array of skin concerns ranging from common dermatological conditions to cosmetic enhancements. With an increasing societal emphasis on appearance and wellness, there's a continuous rise in demand for both therapeutic and aesthetic treatments. Dermatology clinics are pivotal to providing specialized care and driving advancements in dermatological treatments and procedures through innovation. Diagnostic centers & laboratories play a critical role in the dermatological ecosystem by providing essential services for the accurate diagnosis and monitoring of skin conditions. Dermatology drugs are heavily influenced by diagnostic outcomes, which necessitates accurate and comprehensive testing capabilities. These facilities contribute to the personalization of treatment plans based on diagnostic reports, optimizing patient outcomes. With advancements in diagnostic technologies, such as genetic testing and molecular diagnostics, these centers are at the forefront of identifying drug efficacy and potential side effects for individual patients. Hospitals represent a significant sector in the utilization of dermatology drugs, especially for severe and acute skin conditions requiring multidisciplinary care. Hospitals have specialized dermatology wards or units that manage complex cases, offering inpatient and outpatient services. The availability of a broad healthcare professionals ensures comprehensive care that encompasses the latest in dermatological drug therapies.

Regional Insights

In America, the United States dominates the dermatology drugs market due to its robust healthcare infrastructure, high healthcare spending, and presence of leading pharmaceutical companies. The market is characterized by high demand for biologics and novel therapies for treating severe skin conditions, such as psoriasis and atopic dermatitis. Regulatory support from the FDA for fast-track approvals has also been a key driver. The EMEA region presents a diverse landscape for dermatology drugs, with Western Europe being the most developed market. Regulatory frameworks here are stringent, with the EMA overseeing drug approvals. Increased R&D investments and favorable reimbursement policies are driving the market in Europe. Despite having a smaller market share, the Middle East and Africa are experiencing growth due to rising awareness and improving healthcare infrastructure. The Asia Pacific region shows a growing landscape for dermatology drugs, driven by rapid urbanization, increasing disposable incomes, and a large patient pool. Countries including China and India are at the forefront, with governments implementing favorable policies to attract foreign investment in healthcare. The prevalence of generic drugs is high in this region, providing cost-effective treatment options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dermatology Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dermatology Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dermatology Drugs Market, highlighting leading vendors and their innovative profiles. These include Allergan plc by Abbvie Inc., Almirall S.A., Amgen Inc., Arcutis Biotherapeutics, Inc., Asterisk Laboratories, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited, DermBiont, Inc., Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., GlaxoSmithkline plc, Johnson & Johnson Services, Inc., Leo Pharma A/S, Lupin Ltd, Mayne Pharma Group Ltd, Merck & Co., Inc, Novartis AG, Pfizer Inc., Roivant Sciences Ltd., and Shinom Cosmeceuticals.

Market Segmentation & Coverage

This research report categorizes the Dermatology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Therapeutic Class
    • Antifungals
    • Corticosteroids
    • Immunosuppressants
    • Retinoids
  • Route of Administration
    • Oral
    • Parenteral Injection
    • Topical
  • Indication Type
    • Acne
    • Atopic dermatitis
    • Psoriasis
    • Skin cancer
  • End-User
    • Aesthetic & Dermatology Clinics
    • Diagnostic Centers & Laboratories
    • Hospitals
  • Distribution Channel
    • Hospital pharmacies
    • Retail pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dermatology Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dermatology Drugs Market?

3. What are the technology trends and regulatory frameworks in the Dermatology Drugs Market?

4. What is the market share of the leading vendors in the Dermatology Drugs Market?

5. Which modes and strategic moves are suitable for entering the Dermatology Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of skin diseases such as psoriasis, eczema, acne, and skin cancer
      • 5.1.1.2. Technological advancements in drug development, along with a strong pipeline of dermatological drugs
      • 5.1.1.3. Increasing adoption of biologics for treatment-resistant conditions among geriatric condition
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent and time-consuming regulatory approval process
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging investment in personalized medicine, and rising application in telemedicine
      • 5.1.3.2. Notable shift towards natural and organic ingredients in dermatological products
    • 5.1.4. Challenges
      • 5.1.4.1. High treatment costs and stringent regulatory policy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapeutic Class: Proliferation of immunosuppressants in dermatology for the treatment of severe or refractory skin conditions
    • 5.2.2. End-User: High inclination towards aesthetic and dermatology clinics owing to increasing societal emphasis on appearance and wellness
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Dermatology Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Antifungals
  • 6.3. Corticosteroids
  • 6.4. Immunosuppressants
  • 6.5. Retinoids

7. Dermatology Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral Injection
  • 7.4. Topical

8. Dermatology Drugs Market, by Indication Type

  • 8.1. Introduction
  • 8.2. Acne
  • 8.3. Atopic dermatitis
  • 8.4. Psoriasis
  • 8.5. Skin cancer

9. Dermatology Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Aesthetic & Dermatology Clinics
  • 9.3. Diagnostic Centers & Laboratories
  • 9.4. Hospitals

10. Dermatology Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital pharmacies
  • 10.3. Retail pharmacies

11. Americas Dermatology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Dermatology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Dermatology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Almirall and Microsoft announce partnership for the development of novel treatments for skin diseases
    • 14.3.2. FDA Approves Arcutis' ZORYVE (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis
    • 14.3.3. Eli Lilly forays into dermatological space with launch of psoriasis drug
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DERMATOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DERMATOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DERMATOLOGY DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DERMATOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETINOIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETINOIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PARENTERAL INJECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PARENTERAL INJECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ACNE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ACNE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SKIN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AESTHETIC & DERMATOLOGY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AESTHETIC & DERMATOLOGY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 308. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 317. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 318. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 328. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 334. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 336. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 337. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2023 (USD MILLION)
  • TABLE 338. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024-2030 (USD MILLION)
  • TABLE 339. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 20